| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.glenmarklifesciences.com | |
| Market Cap | 5,293.79 Cr. | |
| Enterprise Value(EV) | 4,781.62 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 34.17 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 12.64 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.41 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 167.66 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 2.58 | Calculated using Price: 432.05 |
| Dividend Yield | 4.86 | Period Ending 2021-03 |
| No. of Shares Subscribed | 12.25 Cr. | 122,527,172 Shares |
| FaceValue | 2 | |
| Company Profile | ||
|
Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). It are also increasingly providing contract development and manufacturing operations (CDMO) services to a range of multinational and specialty pharmaceutical companies. It is a research and development (R&D)-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where there is growth potential in the future. Maintaining high standards of process innovation and quality in its R&D and manufacturing operations is critical to its brand and maintenance of long-term relationships with its customers. The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India with an aggregate annual total installed capacity of 726.6 KL as of March 31, 2021. Its R&D laboratories focus on new product development and complex molecules, cost improvement programs, process improvements and oncology product development. To assist it with its R&D initiatives, it has established dedicated teams for new product development, complex products, oncology product development, technology transfer, life cycle management and project management.’ It has a professional and experienced management team. Its management team has demonstrated the ability to successfully build and integrate its businesses with various operating activities through their cumulative years of work experience. In particular, they have led the process through which it has created value through organic growth, built brand recognition and loyalty and identified new business opportunities. Business area of the company The company is in the business of making high-quality drugs by unlocking the possibilities of science. Awards, accreditations and recognitions
Major events and milestones
|
||
Company Profile
Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). It are also increasingly providing contract development and manufacturing operations (CDMO) services to a range of multinational and specialty pharmaceutical companies. It is a research and development (R&D)-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where there is growth potential in the future. Maintaining high standards of process innovation and quality in its R&D and manufacturing operations is critical to its brand and maintenance of long-term relationships with its customers.
The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India with an aggregate annual total installed capacity of 726.6 KL as of March 31, 2021. Its R&D laboratories focus on new product development and complex molecules, cost improvement programs, process improvements and oncology product development. To assist it with its R&D initiatives, it has established dedicated teams for new product development, complex products, oncology product development, technology transfer, life cycle management and project management.’ It has a professional and experienced management team. Its management team has demonstrated the ability to successfully build and integrate its businesses with various operating activities through their cumulative years of work experience. In particular, they have led the process through which it has created value through organic growth, built brand recognition and loyalty and identified new business opportunities.
Business area of the company
The company is in the business of making high-quality drugs by unlocking the possibilities of science.
Awards, accreditations and recognitions
Major events and milestones
| 1 Day |
|
-1.81% |
| 1 Week |
|
-2.25% |
| 1 Month |
|
-13.13% |
| 3 Month |
|
-3.24% |
| 6 Month |
|
-30.48% |
| 1 Year |
|
|
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 4 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 451.05 | 127.84 | 60.91 | ||
| Return on Capital Employed (%) | 527.74 | 185.60 | 96.75 | ||
| Return on Assets (%) | -510.59 | 26.51 | 19.56 | 18.89 |
| Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | -1 | 88 | 402 | 753 | 2,054 | |
| Non Curr. Liab. | 7 | 16 | 23 | 33 | ||
| Curr. Liab. | 1 | 1,380 | 1,307 | 1,221 | 384 | |
| Minority Int. | ||||||
| Equity & Liab. | 0 | 1,475 | 1,726 | 1,997 | 2,471 | |
| Non Curr. Assets | 545 | 565 | 598 | 706 | ||
| Curr. Assets | 0 | 931 | 1,160 | 1,399 | 1,765 | |
| Misc. Exp. not W/O | ||||||
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 |
| Particulars | 5 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 0 | 886 | 1,537 | 1,885 | 2,123 | |
| Other Income | 1 | 12 | 1 | 15 | ||
| Total Income | 0 | 887 | 1,549 | 1,886 | 2,138 | |
| Total Expenditure | 0 | -639 | -1,065 | -1,294 | -1,507 | |
| PBIDT | 0 | 248 | 484 | 592 | 631 | |
| Interest | -1 | -34 | -88 | -28 | ||
| Depreciation | -19 | -29 | -33 | -38 | ||
| Taxation | 0 | -33 | -108 | -119 | -146 | |
| Exceptional Items | ||||||
| PAT | 0 | 196 | 313 | 352 | 419 | |
| Adjusted EPS | -8 | 18 | 29 | 33 | 35 |
| Particulars | 4 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 10 | 195 | 388 | |
| Cash Fr. Inv. | -9 | -51 | -69 | ||
| Cash Fr. Finan. | 0 | 1 | -137 | -214 | |
| Net Change | 0 | 2 | 8 | 106 | |
| Cash & Cash Eqvt | 0 | 2 | 10 | 116 |
|
Fri, 13 May 2022
Announcement under Regulation 30 (LODR)-Monitoring Agency Report Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited Monitoring Agency for the quarter ended 31st March 2022 in respect of utilization of proceeds of the IPO of the Company. |
|
Tue, 10 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Pursuant to the Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are attaching herewith the Annual Secretarial Compliance Report for the year ended 31st March 2022. |
|
Fri, 22 Apr 2022
Audio Recordings Of Q4 & FY22 Earnings Call Pursuant to Regulation 30 and 46 read with clause 15 of Para A of Part A of Schedule Ill of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby confirm that we have uploaded audio recording of the Q4 & FY22 Earnings Call held on April 21 2022 on our investor website : https://www.glenmarklifesciences.com/financial-results.php under Financial Results.We request you to take note and host the same on your website. |
| Tue, 24 May 2022 |
High Delivery Percentage
|
Close Crossing Last Week Low
|
Opening at High
|
Closing Below Previous Low
|
Close Within 52 Week Low Zone
|
Equities
M.F.
Sectors